Home page
01 giugno 2020
Scientific Activities
Carbohydrate Science Group Publications

385. Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential S. Bertini, J. Fareed, L. Madaschi, G. Risi, G. Torri, A.Naggi, Clinical and Applied Thrombosis/Hemostasis (2017) January 1: 1076029616685430
384. Qualification of HSQC methods for quantitative composition of heparin and low molecular weight heparins Mauri, L., Boccardi, G., Torri, G., (...), Keire, D., Guerrini, M.  2017 Journal of Pharmaceutical and Biomedical Analysis 136, p. 92-105
383. Investigating the relationship between temperature, conformation and calcium binding in heparin model oligosaccharides  Hughes, A. Meneghetti, M., Huang, T.-Y., Hung, S.-C., Elli, S., Guerrini, M., Rudd, T., Lima, M., Yates, E 2017 Carbohydrate Research 438, pp. 58-64
382. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat Alekseeva, A., Mazzini, G., Giannini, G., Naggi, A. 2017 Carbohydrate Polymers 156, pp. 470-480
381. Non-anticoagulant heparins are hepcidin antagonists for the treatment of anemia Poli, M., Asperti, M., Ruzzenenti, P., Naggi, A., Arosio, P. 2017 Molecules 22(4),598
380. Simultaneous removal of Cd, Co, Cu, Mn, Ni, and Zn from synthetic solutions on a hemp-based felt. II. Chemical modification Loiacono, S., Crini, G., Martel, B., (...), Torri, G., Morin-Crini, N. 2017 Journal of Applied Polymer Science 134(32),45138
379. Investigating Glycol-Split- Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides. Ni M., Elli S., Naggi A., Guerrini M., Torri G., Petitou M. Molecules 2016, 21(11), 1602
378. Paramètres de l’eau et rejets industriels. Morin-Crini N., Trunfio G., Winterton P., Torri G., Louvard N., Girardot S., Hutinet X. et Crini G. in Eaux industrielles contaminées. Editors MORIN-CRINI N., CRINI G., ROY L. - Presse Universitaires de Franche-Compté, 4, 2017
377. Pollutant removal from industrial discharge water using individual and combined effects of adsorption and ion-exchange processes: Chemical abatement Charles, J., Bradu, C., Morin-Crini, N., Sancey, B., Winterton, P., Torri, G., Badot, P.-M., Crini, G. 2016 Journal of Saudi Chemical Society 20.2 (2016): 185-194
376. Pollutant removal from industrial discharge water using individual and combined effects of adsorption and ion-exchange processes: Chemical abatement Charles, J., Bradu, C., Morin-Crini, N., Sancey, B., Winterton, P., Torri, G., Badot, P.-M., Crini, G. 2016 Journal of Saudi Chemical Society 20.2 (2016): 185-194
375. Old and new applications of non-anticoagulant heparin Cassinelli, G., Naggi, A. 2016 International Journal of Cardiology 212, pp. S14-S21 Heparin centenary–an ever-young life-saving drug. Torri, G., & Naggi, A. (2016). International journal of cardiology, 212, S1-S4.
374. Atomic Details of the Interactions of Glycosaminoglycans with Amyloid-ß Fibrils Stewart, K.L. , Hughes, E., Yates, E.A., Akien, G.R., Huang, T.-Y., Lima, M.A., Rudd, T.R., Guerrini, M., Hung, S.-C., Radford, S.E., Middleton, D.A. 2016 Journal of the American Chemical Society 138(27), pp. 8328-8331
373. Uncovering the Relationship between Sulphation Patterns and Conformation of Iduronic Acid in Heparan Sulphate Hsieh, P.-H., Thieker, D.F., Guerrini, M., Woods, R.J., Liu, J. 2016 Scientific Reports
372. Cross-linked cyclodextrin-based material for treatment of metals and organic substances present in industrial discharge waters Euvrard, É., Morin-Crini, N.Druart, C. Bugnet, J. Martel, B. Cosentino, C. Moutarlier, V. Crini, G 2016 Beilstein Journal of  Organic Chemistry
371. Investigating glycol-split-heparin-derived inhibitors of heparanase: A study of synthetic trisaccharides Ni, M., Elli, S., Naggi, A., (...), Torri, G., Petitou, M. 2016 Molecules 21(11),1602
370. Nuclear Magnetic Resonance and Molecular Dynamics Simulation of the Interaction between Recognition Protein H7 of the Novel Influenza Virus H7N9 and Glycan Cell Surface Receptors Macchi, E., Rudd, T.R., Raman, R., (...), Guerrini, M., Elli, S. 2016 Biochemistry 55(48), pp. 6605-6616
369.  The roots of modern oncology: from discovery of new antitumor anthracyclines to their clinical use. Cassinelli G Tumori. 2016 Apr 21:0. doi: 10.5301/tj.5000507. [Epub ahead of print]
368. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.
Foglieni C, Pagano K, Lessi M, Bugatti A, Moroni E, Pinessi D, Resovi A, Ribatti D, Bertini S, Ragona L, Bellina F, Rusnati M, Colombo G, Taraboletti G. Sci Rep. 2016 Mar 22;6:23432. doi: 10.1038/srep23432.
367. Structural peculiarity and antithrombin binding region profile of mucosal bovine and porcine heparins.
Naggi A, Gardini C, Pedrinola G, Mauri L, Urso E, Alekseeva  A, Casu B, Cassinelli G, Guerrini M, Iacomini M, Baigorria V, Torri G. J Pharm Biomed Anal. 2016 Jan 25;118:52-63. doi: 10.1016/j.jpba.2015.10.001. Epub 2015 Oct 17.
366. Hydration of calcium sulphoaluminate clinker with additions of different calcium sulphate sources
Allevi S, Marchi M, Scotti F, Bertini S, Cosentino C
Materials and Structures  2016, 49(1-2), 453-466.
365. High Sulfation and a High Molecular Weight Are Important for Anti-hepcidin Activity of Heparin.
Asperti M, Naggi A, Esposito E, Ruzzenenti P, Di Somma M, Gryzik M, Arosio P, Poli M. Front Pharmacol. 2016 Jan 11;6:316. doi: 10.3389/fphar.2015.00316. eCollection 2015.
364. Consequence of litter removal on pedogenesis: A case study in Bachs and Irchel (Switzerland).
Scalenghe R, Minoja A P, Zimmermann S, Bertini S
Geoderma, 2016271, 191-201.
363. New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation.
Ni M, Esposito E, Raj VP, Muzi L, Zunino F, Zuco V, Cominetti D, Penco S, Dal Pozzo A. Bioorg Med Chem. 2015 Nov 1;23(21):6785-93. doi: 10.1016/j.bmc.2015.10.004. Epub 2015 Oct 9. Review.
362. Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis.
Guerrini M, Rudd TR, Mauri L, Macchi E, Fareed J, Yates EA, Naggi A, Torri G. Anal Chem. 2015 Aug 18;87(16):8275-83. doi: 10.1021/acs.analchem.5b01366. Epub 2015 Aug 6.

361. Re-visiting the structure of heparin.
Casu B, Naggi A, Torri G. Carbohydr. Res. 2015 Feb 11;403:60-8. doi: 10.1016/j.carres.2014.06.023. Epub 2014 Jul 3. Review.
360. Endogenous origin of foams in lakes: a long-term analysis for Lake Maggiore (northern Italy)
Stefani F, Salerno F, Copetti D, Rabuffetti D, Guidetti L, Torri G, Naggi  A,  Iacomini M, Morabito G, Guzzella L Hydrobiologia 2015, 1-17.
359. Methods of characterization of sulfated polysaccharides. Naggi A and Torri G. In Sulfated Polysaccharides, Eds. Miguel Gama, Helena Nader and Hugo Rocha, Nova Science Publishers 2015, Cap 11 ISBN: 978-1-63483-002-7
358. Heparin derivatives for the targeting of multiple activities in the inflammatory response. Veraldi, N., Hughes, A.J., Rudd, T.R., Thomas, H.B., Edwards, S.W., Hadfield, L., Skidmore, M.A., Siligardi, G., Cosentino, C., Shute, J.K., Naggi, A., Yates, E.A. Carbohydrate Polymers, 117, 400–407, 2015
357. Principales applications des cyclodextrines.
 Morin-Crini, N.,  Torri, G., Fourmentin F., Crini, G. In Cyclodextrines. Histoire, propriétés, chimie & applications. Ed: Morin-Crini, N.,  Fourmentin F., Crini, G. .   Presse Universitaire Franche-Compté,  2015.
356. Determination of the molecular weight of low-molecular-weight heparins by using high-pressure size exclusion chromatography on line with a triple detector array and conventional methods Bisio, A., Mantegazza, A., Vecchietti, D., Bensi D, Coppa A, Torri, G., Bertini, S.  Molecules, 20, 5085-5098, 2015
355. Hydration of calcium sulphoaluminate cement studied by 27Al MAS NMR spectroscopy.  Allevi, S., Marchi, M., Scotti, F., Bertini, S., Cosentino C.  Materials and Structures, 2015 (DOI 10.1617/s11527-014-0510-5).

354. Susceptibility of enoxaparin reducing end amino sugars to periodate oxidation. Alekseeva, A., Elli, S., Cosentino, C., Torri, G., Naggi, A. 
Carbohydrate Research, 400, 33-43, 2014
353. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Poli, M., Asperti, M., Ruzzenenti, P., Ruzzenenti, P. Mandelli, L. Campostrini, N. Martini, G. Di Somma, M. Maccarinelli, F. Girelli, D. Naggi, A. Arosio, P.,
Biochemical Pharmacology , 92, 467-475, 2014 
352. Antithrombin-binding oligosaccharides: structural diversities in a unique function?  Guerrini, M., Mourier, P.A.J., Torri, G., Viskov, C. Glycoconjugate Journal , 31, 409-416, 2014
351. Re-visiting the structure of heparin  Casu, B., Naggi, A., Torri, G.  Carbohydrate Research DOI: 10.1016/j.carres.2014.06.023, 2014
350. Insights into the human glycan receptor conformation of 1918 pandemic hemagglutinin-glycan complexes derived from nuclear magnetic resonance and molecular dynamics studies.  Elli, S., Macchi, E., Rudd, T.R., Elli, S. Raman, R.Sassaki, G.Viswanathan, K.Yates, E.A. Shriver, Z., Naggi, A., Torri, G., Sasisekharan, R. , Guerrini, M.,  
Biochemistry , 53, 4122-4135, 2014
349. Alkylphenol and alkylphenol polyethoxylates in water and wastewater: A review of options for their elimination  Priac, A., Morin-Crini, N., Druart, C., Gavoille, S., Bradu, C.,  Lagarrigue, C.d,  Torri, G., Winterton, P., Crini, G.    Winterton, P., Crini, G. 
Arabian Journal of Chemistry  DOI: 10.1016/j.arabjc.2014.05.011
348. Optimisation of an industrial wastewater decontamination plant: An environment-oriented approach  Charles, J., Crini, G., Bradu, C., Torri, G. Gavoille, S., Sancey, B., Morin-Crini, N.,  Trunfio, G.,  Badot, P.-M., Winterton, P., Lagarrigue, C. 
Canadian Journal of Chemical Engineering, 92, 391-400, 2014
347. A chlorhexidine-loaded biodegradable cellulosic device for periodontal pockets treatment. Tabary, N., Chai, F., Blanchemain, N., Neut, C., Pauchet, L.,  Bertini, S., Delcourt-  Debruyne, E., Hildebrand, H.F., Martel, B.    Acta Biomaterialia 318-329, 2014.
346.   A heparin-like glycosaminoglycan from shrimp containing high levels of 3-O-sulfated D-glucosamine groups in an unusual trisaccaride sequence. Chavante S.F, Brito A.S., Lima M., Yates E.A., Nader H., Guerrini M., Torri G., Bisio A.  Carbohydrate Research 390, 59-66, 2014.
345. Conformational changes of 1-4-glucopyranosyl residues of a sulfated CC linked hexasaccharide. Coletti, A., Elli, S., Macchi, E., Galzerano, P., Zamani, L., Guerrini, M., Torri G., Vismara, E. Carbohydrate Research, 389, 134-140. 2014.
344. Monosaccharide composition of glycans based on Q-HSQC NMR Sassaki, G.L., Guerrini, M.R., Serrato, V., Filho, A.P.S., Carlotto, J., Simas-Tosin, F., Ricardo Cipriani, T.,  Iacomini, M., Torri, G.,  Gorin P.A.J. Carbohydrate Polymers 104, 34-41, 2014
343. Advanced oxidation (UV-ozone) and cyclodextrin sorption: Effects of individual and combined action on the chemical abatement of organic pollutants in industrial effluents. Charles, J., Crini, G., Morin-Crini, N., Badot, P.M., Trunfio, G., Sancey, B., de Carvalho, M., Bradu, C., Avramescu, S., Winterton, P., Gavoille, S., Torri G. Journal Taiwan Inst. Chemical Engineers  45, 603-608, 2014
342. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin. Schlesinger, M., Roblek, M., Ortmann, K., Naggi, A., Torri, G., Borsig, L.R., Bendas. G. Thrombosis Research, 133, 5, 855-862, 2014
341. Glycol-split non-anticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Poli M. Asperti M. Naggi A. Campostrini N. Girelli D. Corbella M. Benzi M. Besson-Fournier C. Coppin H. Maccarinelli F. Finazzi D. Arosio P. Blood. 123(10):1564-73, 2014
340. Non-covalent synthesis of metal oxide nanoparticle–heparin hybrid systems: a new approach to bioactive nanoparticles. Vismara, E., Valerio, A., Coletti, A., Torri, G., Bertini, S., Eisele, G., Gornati, R., Bernardini, G. Int. J. Mol. Sci. 14, 13463-13481, 2013

339. Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments. Alekseeva A., Casu B., Cassinelli G., Guerrini M., Torri G., Naggi A., Anal. Bioanal. Chem., in press (2013).

338. Human (a2–»6) and avian (a2–»3) sialylated receptors of influenza A virus show distinct conformations and dynamics in solution. Sassaki G.L., Elli S., Rudd T.R., Macchi E., Yates E.A., Naggi A., Shiver Z., Raman R., Sasisekharan R., Torri G., Guerrini M., Biochemistry ; 52, 7217-7230 (2013).

337. Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4. Schmitz P., Gerber U., Schütze N., Jüngel E., Blaheta R., Naggi A., Torri G., Bendas G. Thromb. Haemost. ; 110, 1046-1054 (2013).

336. Reversed-phase ion-pair ultra-high-performance-liquid chromatography-mass spectrometry for fingerprinting low-molecular weights heparins. Langeslay D.J., Urso E., Gardini C., Naggi A., Torri G., Larive C.K. J. Chromat. A ; 1292, 201-211 (2013).

335. Update in the recommendations on biosimilar low-molecular weight heparin from the Scientific Subcommitee on Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. Harenberg J., Walenga J., Torri G., Dahl O.E., Drouet L., Fareed J. J. Thromb. Haemost. ; 1421-1425 (2013).

334. Unravelling structural information from complex mixtures utilizing correlation spectroscopy applied to HSQC spectra. Rudd T.R., Macchi E., Muzi L., Ferro M., Gaudesi D., Torri G., Casu B., Guerrini M., Yates E.A. Anal. Chem. ; 85, 7487-7493 (2013).

333. Heparin dodecasaccharide containing two antithrombin-binding pentasaccharides. Structural features and biological properties. Viskov C., Elli S., Gaudesi D., Mourier P., Herman F., Boudiel C., Casu B., Torri G., Guerrini M. J. Biol. Chem. 2013;…….

332. Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides. Alekseeva A., Casu B., Torri G., Pierro S., Naggi A. Anal. Chem. ; 434, 112-122 (2013).

331 Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis. Langeslay D.J., Beecher C.N., Naggi A., Guerrini M., Torri G. and Larive C.K. Anal. Chem. ; 85, 1247-1255 (2013).

330. An unusual antithrombin-binding heparin octasaccharide with an additional 3-O-complexsulfated glucosamine in the active pentasaccharide sequence. Guerrini M., Elli S., Mourier P., Rudd T.R., Gaudesi D., Casu B., Boudier C., Torri G., Viskov C. Biochem. J. , 449, 343-351 (2013).


329. Anti-metastatic semi-synthetic sulphated maltotriose C-C linked dimers. Synthesis and characterization. Vismara E., Coletti A., Valerio A., Naggi A., Urso E., Torri G. Molecules , 17, 9912-9930 (2012).

328. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. Schlesinger M., Schmitz P., Zeisig R., Naggi A., Casu B., Torri G., Bendas G. Thromb. Res. ; 129, 603-610 (2012).

327. How to find a needle (or anything else) in a haystack: Two-Dimensional Correlation Spectroscopy-Filtering with iterative random sampling applied to pharmaceutical heparin. Rudd T.R., Macchi E., Gardini C., Muzi L., Guerrini M., Yates E.A., Torri G.. Anal Chem. ; 84, 6841-6847 (2012).

326. A zinc complex of heparan sulfate destabilises lysozime and alters its conformation. Hughes R., Hussain R., Cosentino C., Guerrini M., Siligardi G., Yates EA, Rudd T.R., Bioichem. Biophys. Res. Comm. ; 425, 794-799 (2012).

325. Following protein-glycosaminoglycan polysaccharide interactions with differential scanning fluorimetry. Uniewicz, K.A., Ori, A., Rudd, T.R., Guerrini, M., Wilkinson, M.C., Ferning, D.G., Yates, E.A., Methods Mol. Biol. ; 836, 171-182 (2012).

324. Chitosan-graft-branched polyethylenimine copolymers: influence of degree of grafting on transfection behavior. Pezzoli D., Olimpieri F., Malloggi C., Bertini S., Volonterio A., et al.  PLoS ONE 7: e34711 (2012).

323. Low-Molecular-Weight heparins: differential characterization/physical characterization. Guerrini M., Bisio A., HEPARIN - A CENTURY OF PROGRESS. Handbook of Experimental Pharmacology, ; 207, Part 2, 127-157 (2012).

322. Heparin-like heparan sulfate from rabbit cartilage. Parra A, Veraldi N., Locatelli M., Fini M., Martini L., Torri G., Sangiorgi L., Bisio A., Glycobiology ; 22, 248-257 (2012).

321. Following protein-glycosaminoglycan polysaccharide interactions with differential scanning fluorimetry. Uniewicz KA,. Ori A., Rudd TR., Guerrini M., Wilkinson MC., Fernig D.G., Yates EA,. Methods in Molecular Biology. ; 836:171-182 (2012).


320. Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-beta1 expression in mesangial cells: biochemical and structural considerations. Bacilieri M., Naggi A,. Ceol M., Schleicher ED., Tosetto E., Comoli M., Torri G., Moro S., Palumbo M., Gambaro G., Glycobiology.; 21, 1029-1037 (2011).

319. Radical-based grafting of GMA on sutures of different nature. Alberti A., Fuochi P., Guerra M., Macciantelli D., Torri G., Valerio A., Vismara E. Organic & Biomolecular Chemistry. ; 9, 3199-3204 (2011).

318. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Borsig L., Vlodavsky I., Ishai-Michaeli R., Torri G., Vismara E. Neoplasia. ; 13, 45-52 (2011).

317. A robust method to quantify low molecular weight contaminants in heparin: detection of tris(2-n-butoxyethyl) phosphate. Sassaki GL, Riter DS, Santana Filho AP, Guerrini M, Lima MA, Cosentino C, Souza LM, Cipriani TR, Rudd TR, Nader HB, Yates EA, Gorin PA, Torri G, Iacomini M. Analyst ;136, 2330-2338 (2011).

316. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y. Clin Cancer Res. ;17,1382-93 (2011).

315. High-sensitivity visualisation of contaminants in heparin samples by spectral filtering of 1H NMR spectra. Rudd TR, Gaudesi D, Lima MA, Skidmore MA, Mulloy B, Torri G, Nader HB, Guerrini M, Yates EA. Analyst ;136,1390-1398 (2009).

314. Construction and use of a library of bona fide heparins employing 1H NMR and multivariate analysis. Rudd TR, Gaudesi D, Skidmore MA, Ferro M, Guerrini M, Mulloy B, Torri G, Yates EA. Analyst ;136,1380-1389 (2011).

313. Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Baud'huin M, Ruiz-Velasco C, Jego G, Charrier C, Gasiunas N, Gallagher J, Maillasson M, Naggi A, Padrines M, Redini F, Duplomb L, Heymann D. Eur. J. Cell Biol. ;90:49-57 (2011).


312. BloRuddcking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins. Schlesinger M, Naggi A, Torri G, Zeisig R, Alexander M, Schmitz P, Casu B, Bendas G. Int. J. Clin. Pharmacol. Ther.; 48,448 -450 (2010).

311. Comparable stabilisation , structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Rudd T.R., Uniewicz K.A., Ori A., Sikmore N.A., Gaudesi D., Xu R., Turnbull J.E., Guerrini M. Torri G., Siligardi G., Wilkinson M.C., Fernig D.G., Yates E.A., Org. Biomol. Chem ; 8, 5390-5397 (2010).

310. Modeling the adsorption behavior of linear end-functionalized poly(ethylene glycol) on an ionic substrate by a coarse-grained Monte Carlo approach. Elli S., Eusebio L., Gronchi P., Ganazzoli F., Goisis M. Langmuir ; 26, 15814- 15823 (2010).

309. Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Rudd TR, Uniewicz KA, Ori A, Guimond SE, Skidmore MA, Gaudesi D, Xu R, Turnbull JE, Guerrini M, Torri G, Siligardi G, Wilkinson MC, Fernig DG, Yates EA. Org Biomol Chem. ; 8, 5390-5397 (2010).

308. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Casu B, Naggi A, Torri G. Matrix Biol. ; 29, 442-452 (2010).

307. The conformation and structure of GAGs: Recent progress and perspectives. Rudd T.R., Skidmore M.A., Guerrini M., Hricovini M., Powell A.K., Siligardi G. and Yates E.A. Curr. Op. Struct. Biol. ; 20, 1-8 (2010).

306. Characterization and binding activity of the chondroitin / dermatan sulphate chain from endocan, a soluble endothelial proteoglycan. Sarrazin S., Lyon M., Deakin J.A., Guerrini M., Lassalle P., Delehedde M., Lortat-Jacob H. Glycobiology  (2010);….

305. Conformation rather than sequence determines polysaccharide activity with fibroblast growth factors-1 and -2. Rudd TR., Uniewicz KA., Ori A., Guimond SE., Skidmore MA., Gaudesi D., Xu R., Stafford-Jones T., Holman J., Turnbull JE., Guerrini M., Torri G., Siligardi G., Wilkinson M., Fernig DG.,Yates EA. Org. Biomol. Chem. ….

304. Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin. Guerrini M., Elli S., Gaudesi D., Torri G., Casu B., Mourier P., Herman F., Boudier C., Lorenz M. and Viskov C. J. Med. Chem. ; 53, 8030-8040 (2010).

303. Correspondence: Oversulfated chondroitin sulfate is the major contaminant in suspected heparin lots collected in February/March of 2008. Guerrini M., Zhang, F., Shriver Z., Naggi A., Casu B., Linhardt R. J., Torri G., Sasisekharan R. Nature Biotechnol. ; 28, 207-211 (2010).

302. Extraction and structural characterization of the polysaccharide fraction of Launaea acanthodes gum. Piazza L., Bertini S., Milany J. Carbohydr. Polymers ; 79, 449-454 (2010).

301. Low molecular weight heparin from Cu2+ and Fe2+ Fenton’s type depolymerisation processes. Vismara E., Pierini M., Mascellani G., Liverani L., Lima M., Guerrini M., Torri G. Thrombosis Haemostasis, ; 103, 613-622 (2010).


300. Ortogonal analytical approches to detect potential contaminants in Heparin. Guerrini M., Zhang Z., Shriver Z., Masuko S., Torri G., Naggi A., Langer R., Casu B., Linhardt R., Sasisekharan R. Proc. Natl. Acad. Sci., 106:16956-16961 (2009).

299. Surface functionalization of cotton cellulose with glycidyl methacrylate and its application for the adsorption of aromatic pollutants from wastewaters. Vismara E., Melone L., Gastaldi G., Cosentino C., Torri G. J. Hazardous Materials. 170; 798-808 (2009).

298. Electrochemical characterization of 6-iodomaltose, 6’-iodomaltose and 6-iodomaltotriose on silver cathode and their one-pot electrochemical dimerisation to new mixed O/C maltotetraose and maltohexaose mimics. Alberti A., Macciantelli D., Naggi A., Urso E., Torri G., Vismara E.. Chemistry DOI: 10.1002/chem.200 (2009).

297. Multi-scale estimation of water soluble diffusivity in polysaccharide gels. L Piazza, J Gigli, S Bertini, G Eisele. Proceedings of Intern. Symp. on Food Rheology and Structure; ed. P. Fischer, M. Pollard and E J Windhab. ETH Zurich (2009) …

296. “Focusing” of low-molecular-mass heparins in polycationic poly-acrylamide matrices. Zilberstein G.K. L., Shlar I., Fasoli E., Righetti P., Torri G., Bisio A.; Bukshpan S., Anal. Chem. 81: 6966-6971 (2009).

295. Structural features of low molecular weight heparins affecting their affinity to antithrombin. A. Bisio, D. Vecchietti, L. Citterio, M. Guerrini, R. Raman, S. Bertini, G. Eisele, A. Naggi, R. Sasisekharan, G. Torri. Thromb. Haemost. 102: 865-873 (2009).

294. The tainted heparin story: an update. M. Guerrini, Z. Shriver, A. Bisio, A. Naggi, B.Casu, R. Sasisekharan, G. Torri. Thromb. Haemost. 2009; 102: 907-911.

293. Chitine et Chitosane. Préparation, propriétés et principales applications . G. Crini, É. Guibal, M. Morcellet, G. Torri et P.-M. Badot. In Chitine et Chitosane. Du biopolymère à l’application, coordonné par Grégorio Crini, Pierre-Marie Badot et Éric Guibal, édité par les Presses Universitaires de Franche-Comté; Chap I, 19-54. ISBN 978-2-84867-249-6 (2009).

292. Cations modulate polysaccharide structure to determine FGF-FGFR signaling: a comparison of signaling and inhibitory polysaccharide interactions with FGF-1 in solution. Guimond SE, Rudd TR, Skidmore MA, Ori A, Gaudesi D, Cosentino C, Guerrini M, Edge R, Collison D, McInnes E, Torri G, Turnbull JE, Fernig DG, Yates EA. Biochemistry 48:4772-4779 (2009).

291. Recommendations on biosimilar low-molecular-weight heparins. Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J, Mismetti P, Ofosu FA, Raake W, Samama M, Schulman S, on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 7, 1222-1225 (2009).

290. Glycosaminoglycan origin and structure revealed by multivariate analysis of NMR and CD spectra. Rudd TR, Skidmore MA, Guimond SE, Cosentino C, Torri G, Fernig DG, Lauder RM, Guerrini M, Yates EA. Glycobiology; 19:52-67 (2009).

289. Exploiting the cross-metathesis reaction in the synthesis of pseudo-oligosaccharides. Ronchi P, Vignando S, Guglieri S, Polito L, Lay L. Org. Biomol. Chem.; 7: 2635–2644 (2009).

288. Heparin and its derivatives - Present and future. Harenberg J., Casu B. Thromb. Haemost. 2009; 102, 801-802.